Tag Archives: IP

Innovative China: Policies for the Future

China Flag

As the second largest and fastest growing market for biotechnology products, China needs no introduction.  The opportunity to heal, fuel, and feed 1.3 billion global citizens stands in clear contrast with the regulatory, financial, and political frameworks that present challenges to the life science industry’s external access to the evolving Chinese market.  On Tuesday at the 2011 BIO International Convention, a panel discussion titled “Innovative China: Policies for the Future” addressed the future of the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Blogging from #BIO2011

by Stephen Albainy-Jenei, from Patent Baristas You can keep up with what’s happening at BIO 2011 on BIOTechNOW (@BIOTechNOW) plus all the BIO Official Bloggers hitting the floor at the convention. I’ll be in attendance as well as participating in the BIO Official Blogger network throughout the week.   If you’d like to meet up during the conference, drop me a note and we’ll schedule some time to have coffee together.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Docs at BIO: Patent Litigation Tactics and Strategies for Biosimilars

One of the highlights of the afternoon sessions at the BIO International Convention was a seminar appropriately entitled “A Brave New World: Patent Litigation Tactics and Strategies for Biosimilars,” where an experienced panel of patent attorneys presented their interpretation of the new biosimilars pathway of the Biologics Price Competition and Innovation Act and speculated on some of the potential issues that will arise once the statute is put into practice.  From Patent Docs.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Intellectual Property problems for personalized medicine

Amid growing interest in personalized medicine that stands to provide patients with better care at reduced costs, legal battles over gene patents ensue, threatening the viability of widespread implementation. On this topic authors Jennifer Gordon, Steve Lendaris and Anna Volftsun (layers at Baker Botts LLP) wrote a very interesting opinion article for The Scientist on the topic. They also examine the barriers to personalized medicine, including a pending decision in the Myriad Genetics case, and Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO’s IP Priorities for 2011

As we start a new year, the BIO Intellectual Property Department has determined their 2011 priorities.  Intellectual Property remains a foundational priority for BIO and our 1100 biotechnology company members. BIO’s IP department has approved the following priorities for 2011: 1) PTO reforms to improve efficient, timely and quality examination 2) Congressional patent reform legislation 3) Improving IP protection in key foreign markets 4) IP legal developments in the courts 5) Protecting the breadth and flexibility of the patent Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,